Cargando…
Met-RANTES preserves the blood–brain barrier through inhibiting CCR1/SRC/Rac1 pathway after intracerebral hemorrhage in mice
BACKGROUND: C–C chemokine receptor type 1 (CCR1) and its endogenous ligand, CCL5, participate in the pathogenesis of neuroinflammatory diseases. However, much remains unknown regarding CCL5/CCR1 signaling in blood–brain barrier (BBB) permeability after intracerebral hemorrhage (ICH). METHODS: A tota...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781527/ https://www.ncbi.nlm.nih.gov/pubmed/35062973 http://dx.doi.org/10.1186/s12987-022-00305-3 |
_version_ | 1784638099784990720 |
---|---|
author | Yan, Jun Xu, Weilin Lenahan, Cameron Huang, Lei Ocak, Umut Wen, Jing Li, Gaigai He, Wei Le, Chensheng Zhang, John H. Mo, Ligen Tang, Jiping |
author_facet | Yan, Jun Xu, Weilin Lenahan, Cameron Huang, Lei Ocak, Umut Wen, Jing Li, Gaigai He, Wei Le, Chensheng Zhang, John H. Mo, Ligen Tang, Jiping |
author_sort | Yan, Jun |
collection | PubMed |
description | BACKGROUND: C–C chemokine receptor type 1 (CCR1) and its endogenous ligand, CCL5, participate in the pathogenesis of neuroinflammatory diseases. However, much remains unknown regarding CCL5/CCR1 signaling in blood–brain barrier (BBB) permeability after intracerebral hemorrhage (ICH). METHODS: A total of 250 CD1 male mice were used and ICH was induced via autologous whole blood injection. Either Met-RANTES, a selective CCR1 antagonist, or Met-RANTES combined with a Rac1 CRISPR activator was administered to the mice 1 h after ICH. Post-ICH assessments included neurobehavioral tests, brain water content, BBB integrity, hematoma volume, Western blot, and immunofluorescence staining. The CCR1 ligand, rCCL5, and SRC CRISPR knockout in naïve mice were used to further elucidate detrimental CCL5/CCR1/SRC signaling. RESULTS: Brain endogenous CCR1 and CCL5 were upregulated after ICH in mice with a peak at 24 h, and CCR1 was expressed in endothelial cells, astrocytes, and neurons. Met-R treatment reduced brain edema and neurobehavioral impairment, as well as preserved BBB integrity and tight junction protein expression in ICH mice. Met-R treatment decreased expression of p-SRC, Rac1, albumin, and MMP9, but increased claudin-5, occludin, and ZO-1 tight junction proteins after ICH. These effects were regressed using the Rac1 CRISPR activator. Administration of rCCL5 in naïve mice increased expression of p-SRC, Rac1, albumin, and MMP9, but decreased levels of claudin-5, occludin, and ZO-1 tight junction proteins. These effects in naïve mice were reversed with SRC CRISPR (KO). CONCLUSIONS: Our findings demonstrate that CCR5 inhibition by Met-R improves neurological deficits after ICH by preserving BBB integrity through inhibiting CCR1/SRC/Rac1 signaling pathway in mice. Thus, Met-R has therapeutic potential in the management of ICH patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12987-022-00305-3. |
format | Online Article Text |
id | pubmed-8781527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87815272022-01-24 Met-RANTES preserves the blood–brain barrier through inhibiting CCR1/SRC/Rac1 pathway after intracerebral hemorrhage in mice Yan, Jun Xu, Weilin Lenahan, Cameron Huang, Lei Ocak, Umut Wen, Jing Li, Gaigai He, Wei Le, Chensheng Zhang, John H. Mo, Ligen Tang, Jiping Fluids Barriers CNS Research BACKGROUND: C–C chemokine receptor type 1 (CCR1) and its endogenous ligand, CCL5, participate in the pathogenesis of neuroinflammatory diseases. However, much remains unknown regarding CCL5/CCR1 signaling in blood–brain barrier (BBB) permeability after intracerebral hemorrhage (ICH). METHODS: A total of 250 CD1 male mice were used and ICH was induced via autologous whole blood injection. Either Met-RANTES, a selective CCR1 antagonist, or Met-RANTES combined with a Rac1 CRISPR activator was administered to the mice 1 h after ICH. Post-ICH assessments included neurobehavioral tests, brain water content, BBB integrity, hematoma volume, Western blot, and immunofluorescence staining. The CCR1 ligand, rCCL5, and SRC CRISPR knockout in naïve mice were used to further elucidate detrimental CCL5/CCR1/SRC signaling. RESULTS: Brain endogenous CCR1 and CCL5 were upregulated after ICH in mice with a peak at 24 h, and CCR1 was expressed in endothelial cells, astrocytes, and neurons. Met-R treatment reduced brain edema and neurobehavioral impairment, as well as preserved BBB integrity and tight junction protein expression in ICH mice. Met-R treatment decreased expression of p-SRC, Rac1, albumin, and MMP9, but increased claudin-5, occludin, and ZO-1 tight junction proteins after ICH. These effects were regressed using the Rac1 CRISPR activator. Administration of rCCL5 in naïve mice increased expression of p-SRC, Rac1, albumin, and MMP9, but decreased levels of claudin-5, occludin, and ZO-1 tight junction proteins. These effects in naïve mice were reversed with SRC CRISPR (KO). CONCLUSIONS: Our findings demonstrate that CCR5 inhibition by Met-R improves neurological deficits after ICH by preserving BBB integrity through inhibiting CCR1/SRC/Rac1 signaling pathway in mice. Thus, Met-R has therapeutic potential in the management of ICH patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12987-022-00305-3. BioMed Central 2022-01-21 /pmc/articles/PMC8781527/ /pubmed/35062973 http://dx.doi.org/10.1186/s12987-022-00305-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yan, Jun Xu, Weilin Lenahan, Cameron Huang, Lei Ocak, Umut Wen, Jing Li, Gaigai He, Wei Le, Chensheng Zhang, John H. Mo, Ligen Tang, Jiping Met-RANTES preserves the blood–brain barrier through inhibiting CCR1/SRC/Rac1 pathway after intracerebral hemorrhage in mice |
title | Met-RANTES preserves the blood–brain barrier through inhibiting CCR1/SRC/Rac1 pathway after intracerebral hemorrhage in mice |
title_full | Met-RANTES preserves the blood–brain barrier through inhibiting CCR1/SRC/Rac1 pathway after intracerebral hemorrhage in mice |
title_fullStr | Met-RANTES preserves the blood–brain barrier through inhibiting CCR1/SRC/Rac1 pathway after intracerebral hemorrhage in mice |
title_full_unstemmed | Met-RANTES preserves the blood–brain barrier through inhibiting CCR1/SRC/Rac1 pathway after intracerebral hemorrhage in mice |
title_short | Met-RANTES preserves the blood–brain barrier through inhibiting CCR1/SRC/Rac1 pathway after intracerebral hemorrhage in mice |
title_sort | met-rantes preserves the blood–brain barrier through inhibiting ccr1/src/rac1 pathway after intracerebral hemorrhage in mice |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781527/ https://www.ncbi.nlm.nih.gov/pubmed/35062973 http://dx.doi.org/10.1186/s12987-022-00305-3 |
work_keys_str_mv | AT yanjun metrantespreservesthebloodbrainbarrierthroughinhibitingccr1srcrac1pathwayafterintracerebralhemorrhageinmice AT xuweilin metrantespreservesthebloodbrainbarrierthroughinhibitingccr1srcrac1pathwayafterintracerebralhemorrhageinmice AT lenahancameron metrantespreservesthebloodbrainbarrierthroughinhibitingccr1srcrac1pathwayafterintracerebralhemorrhageinmice AT huanglei metrantespreservesthebloodbrainbarrierthroughinhibitingccr1srcrac1pathwayafterintracerebralhemorrhageinmice AT ocakumut metrantespreservesthebloodbrainbarrierthroughinhibitingccr1srcrac1pathwayafterintracerebralhemorrhageinmice AT wenjing metrantespreservesthebloodbrainbarrierthroughinhibitingccr1srcrac1pathwayafterintracerebralhemorrhageinmice AT ligaigai metrantespreservesthebloodbrainbarrierthroughinhibitingccr1srcrac1pathwayafterintracerebralhemorrhageinmice AT hewei metrantespreservesthebloodbrainbarrierthroughinhibitingccr1srcrac1pathwayafterintracerebralhemorrhageinmice AT lechensheng metrantespreservesthebloodbrainbarrierthroughinhibitingccr1srcrac1pathwayafterintracerebralhemorrhageinmice AT zhangjohnh metrantespreservesthebloodbrainbarrierthroughinhibitingccr1srcrac1pathwayafterintracerebralhemorrhageinmice AT moligen metrantespreservesthebloodbrainbarrierthroughinhibitingccr1srcrac1pathwayafterintracerebralhemorrhageinmice AT tangjiping metrantespreservesthebloodbrainbarrierthroughinhibitingccr1srcrac1pathwayafterintracerebralhemorrhageinmice |